$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000082787116000064 Filed on May 10, 2016

Income Statement

Concept	2016 Q1	2015 Q1
Revenue	$29.59M	$36.31M
YoY Change	-18.5%	625.45%
Cost Of Revenue	$14.59M	$5.948M
YoY Change	145.28%	77.02%
Gross Profit	$15.00M	$30.36M
YoY Change	-50.59%	1745.65%
Gross Profit Margin	50.7%	83.62%
Selling, General & Admin	$12.13M	$3.986M
YoY Change	204.26%	174.14%
% of Gross Profit	80.84%	13.13%
Research & Development	$5.521M	$6.285M
YoY Change	-12.16%	65.66%
% of Gross Profit	36.8%	20.7%
Depreciation & Amortization	$140.0K	$12.00K
YoY Change	1066.67%	-58.62%
% of Gross Profit	0.93%	0.04%
Operating Expenses	$30.49M	$16.22M
YoY Change	87.98%	88.42%
Operating Profit	-$897.0K	$20.09M
YoY Change	-104.46%	-657.59%
Interest Expense	$0.00	$1.000K
YoY Change	-100.0%	0.0%
% of Operating Profit		0.0%
Other Income/Expense, Net	$20.00K	$6.000K
YoY Change	233.33%	-101.6%
Pretax Income	-$877.0K	$20.10M
YoY Change	-104.36%	-605.05%
Income Tax	$19.00K	$399.0K
% Of Pretax Income		1.99%
Net Earnings	-$896.0K	$19.70M
YoY Change	-104.55%	-833.87%
Net Earnings / Revenue	-3.03%	54.25%
Basic Earnings Per Share	-$0.06	$1.38
Diluted Earnings Per Share	-$0.06	$1.31
COMMON SHARES
Basic Shares Outstanding	15.64M shares	14.25M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$78.30M	$115.9M
YoY Change	-32.44%	111.11%
Cash & Equivalents	$78.29M	$99.92M
Short-Term Investments		$16.00M
Other Short-Term Assets	$207.0K	$174.0K
YoY Change	18.97%	-17.94%
Inventory	$7.761M	$2.018M
Prepaid Expenses
Receivables	$26.53M	$10.51M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$114.6M	$129.8M
YoY Change	-11.69%	104.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.869M	$100.0K
YoY Change	2769.0%	-73.51%
Goodwill
YoY Change
Intangibles	$11.12M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$94.00K	$45.00K
YoY Change	108.89%	0.0%
Total Long-Term Assets	$14.08M	$145.0K
YoY Change	9609.66%	-65.68%
TOTAL ASSETS
Total Short-Term Assets	$114.6M	$129.8M
Total Long-Term Assets	$14.08M	$145.0K
Total Assets	$128.7M	$129.9M
YoY Change	-0.95%	103.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.30M	$5.435M
YoY Change	89.42%	121.09%
Accrued Expenses	$19.56M	$15.03M
YoY Change	30.16%	111.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$30.87M	$27.05M
YoY Change	14.12%	40.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$30.87M	$27.05M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$36.40M	$27.00M
YoY Change	34.81%	39.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$108.0M	-$89.99M
YoY Change	20.03%	-2.34%
Common Stock	$15.00K	$15.00K
YoY Change	0.0%	6.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$92.32M	$102.9M
YoY Change
Total Liabilities & Shareholders Equity	$128.7M	$129.9M
YoY Change	-0.95%	103.16%

Cashflow Statement

Concept	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$896.0K	$19.70M
YoY Change	-104.55%	-833.87%
Depreciation, Depletion And Amortization	$140.0K	$12.00K
YoY Change	1066.67%	-58.62%
Cash From Operating Activities	$3.108M	$25.84M
YoY Change	-87.97%	-1347.51%
INVESTING ACTIVITIES
Capital Expenditures	$804.0K	$43.00K
YoY Change	1769.77%	53.57%
Acquisitions
YoY Change
Other Investing Activities	-$3.100M	-$36.00M
YoY Change	-91.39%
Cash From Investing Activities	-$3.904M	-$16.04M
YoY Change	-75.66%	57189.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$54.70M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	$55.26M
YoY Change	-100.0%	17.56%
NET CHANGE
Cash From Operating Activities	$3.108M	$25.84M
Cash From Investing Activities	-$3.904M	-$16.04M
Cash From Financing Activities	$0.00	$55.26M
Net Change In Cash	-$796.0K	$65.06M
YoY Change	-101.22%	44.87%
FREE CASH FLOW
Cash From Operating Activities	$3.108M	$25.84M
Capital Expenditures	$804.0K	$43.00K
Free Cash Flow	$2.304M	$25.79M
YoY Change	-91.07%	-1328.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15636387	shares
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	EAGLE PHARMACEUTICALS, INC.
CY2015Q4	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	9232000	USD
CY2016Q1	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	5918000	USD
CY2015Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1784000	USD
CY2016Q1	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1258000	USD
CY2015Q1	egrx	Accrued Stock Issuance Costs AccruedStockIssuanceCosts	365000	USD
CY2016Q1	egrx	Accrued Stock Issuance Costs AccruedStockIssuanceCosts	0	USD
CY2015Q1	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	53000	USD
CY2016Q1	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	107000	USD
CY2015Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-300000	USD
CY2016Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	183000	USD
CY2016Q1	egrx	Number Of Products NumberOfProducts	5	product
CY2016Q1	egrx	Numberof Sales Representatives Hired NumberofSalesRepresentativesHired	12	person
CY2015Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	551000	USD
CY2016Q1	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	373000	USD
CY2015Q4	egrx	Prepaid Product Costs PrepaidProductCosts	85000	USD
CY2016Q1	egrx	Prepaid Product Costs PrepaidProductCosts	134000	USD
CY2015Q4	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	283000	USD
CY2016Q1	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	194000	USD
CY2016Q1	egrx	Royalty Revenue Commercial Partners Obligationof Sales Report Term RoyaltyRevenueCommercialPartnersObligationofSalesReportTerm	P60D
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3857000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10295000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26267000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26526000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24405000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19561000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	792000	USD
CY2016Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	817000	USD
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2242000	USD
CY2016Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1149000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	197440000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200309000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2869000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	384000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2869000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	104000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	118619	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2510702	shares
CY2015Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2016Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2015Q4	us-gaap	Assets Assets	124605000	USD
CY2016Q1	us-gaap	Assets Assets	128701000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	122257000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	114622000	USD
CY2015Q1	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	0	USD
CY2016Q1	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	6370000	USD
CY2015Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2016Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	159000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2016Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1012000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2016Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5517000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34869000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99924000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79083000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78287000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	65055000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-796000	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15636387	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15636387	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15636387	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15636387	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2015Q1	us-gaap	Cost Of Revenue CostOfRevenue	5948000	USD
CY2016Q1	us-gaap	Cost Of Revenue CostOfRevenue	14589000	USD
CY2015Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	521000	USD
CY2016Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	538000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6000000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2015Q1	us-gaap	Depreciation Depreciation	12000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	140000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.38
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.31
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2016Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18Y
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	104000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	8156000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	468000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	623000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	623000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	623000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	623000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	0	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11220000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11116000	USD
CY2015Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2016Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1750000	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-273000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	20096000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-877000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1884000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6438000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1448000	USD
CY2016Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	399000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000	USD
CY2015Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	259000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2549000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4844000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	65000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6000000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	776000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7281000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-49000	USD
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	793992	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11116000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	1000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	1000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	1000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	1000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	311000	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2553000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	15042000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	7761000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8687000	USD
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5208000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	6044000	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	7000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	21000	USD
CY2015Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	68000	USD
CY2016Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	162000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	124605000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	128701000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34262000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	30868000	USD
CY2013Q4	us-gaap	Loss Contingency Patents Allegedly Infringed Number LossContingencyPatentsAllegedlyInfringedNumber	1	patent
CY2016Q1	us-gaap	Loss Contingency Patents Allegedly Infringed Number LossContingencyPatentsAllegedlyInfringedNumber	2	patent
CY2015Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	959000	USD
CY2016Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2404000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55260000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16041000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3904000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	25836000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3108000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	19697000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-896000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	19697000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-896000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	19697000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-896000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	16219000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	30488000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	20090000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-897000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2396000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	281000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	564000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	564000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	423000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	USD
CY2016Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	428000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	564000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	220000	USD
CY2016Q1	us-gaap	Other Assets Current OtherAssetsCurrent	207000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	143000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	94000	USD
CY2015Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	30000000	USD
CY2016Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	6000000	USD
CY2015Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2016Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	4850000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	43000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	804000	USD
CY2015Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	15998000	USD
CY2016Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	62000000	USD
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1865000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2048000	USD
CY2015Q4	us-gaap	Prepaid Insurance PrepaidInsurance	218000	USD
CY2016Q1	us-gaap	Prepaid Insurance PrepaidInsurance	651000	USD
CY2015Q4	us-gaap	Prepaid Taxes PrepaidTaxes	508000	USD
CY2016Q1	us-gaap	Prepaid Taxes PrepaidTaxes	489000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	6500000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	54696000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
CY2016Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	62000000	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1750000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	564000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2205000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2869000	USD
CY2016Q1	us-gaap	Purchase Obligation PurchaseObligation	21345000	USD
CY2016Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	21345000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6285000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14122000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	36309000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6676000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107112000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108008000	USD
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	3253000	USD
CY2016Q1	us-gaap	Royalty Revenue RoyaltyRevenue	9469000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3056000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	29591000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3986000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10973000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	384000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2869000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3038
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3131
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0192
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0190
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0163
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0129
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	90343000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	92316000	USD
CY2015Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15041011	shares
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15636387	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14247019	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15636387	shares
CY2016Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and related notes included in our annual report on Form 10-K for the fiscal year ended December 31, 2015, filed with the SEC on February 29, 2016.</font></div></div>
CY2016Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation.</font></div></div>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000827871-16-000064-index-headers.html	Edgar Link	pending
0000827871-16-000064-index.html	Edgar Link	pending
0000827871-16-000064.txt	Edgar Link	pending
0000827871-16-000064-xbrl.zip	Edgar Link	pending
egrx-20160331.xml	Edgar Link	completed
egrx-20160331.xsd	Edgar Link	pending
egrx-20160331_cal.xml	Edgar Link	unprocessable
egrx-20160331_def.xml	Edgar Link	unprocessable
egrx-20160331_lab.xml	Edgar Link	unprocessable
egrx-20160331_pre.xml	Edgar Link	unprocessable
egrx_q1x2016.htm	Edgar Link	pending
exhibit311q12016.htm	Edgar Link	pending
exhibit312q12016.htm	Edgar Link	pending
exhibit321q12016.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2016 Q1 Form 10-Q Financial Statement

#000082787116000064 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2016 Q1 Form 10-Q Financial Statement

#000082787116000064 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx